MedTrace Logo

Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure

NCT01001312 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2015-10-09

No results posted yet for this study

Summary

Heart failure is a common cardiac condition affecting nearly 6 million Americans. Silent blood volume overload is common in patients with heart failure and is associated with increased risk of death. This study is designed to determine if adjustment of therapy based on direct measurement of blood volume will reduce risk of hospitalization and death when compared with therapy based on clinical assessment of blood volume in patients with chronic heart failure.

Conditions

Interventions

OTHER

Daxor Blood Volume Analysis

Radiolabeled albumin for direct measurement of blood volume

OTHER

Clinical volume status assessment

Volume assessment based on history and physical examination

Sponsors & Collaborators

Principal Investigators

  • Stuart D Katz, M.D. · NYU School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-03-31
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01001312 on ClinicalTrials.gov